ArticleJournal of hematology & oncology2023

Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study.

Pierfrancesco Tassone et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.